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We investigated the relationship of End-to-end distance between VH and VL with
different peptide linkers and the activity of single-chain antibodies by
computer-aided simulation. First, we developed (G4S)n (where n = 1-9) as the linker
to connect VH and VL, and estimated the 3D structure of single-chain Fv antibody
(scFv) by homologous modeling. After molecular models were evaluated and
optimized, the coordinate system of every protein was built and unified into one
coordinate system, and End-to-end distances calculated using 3D space coordinates.
After expression and purification of scFv-n with (G4S)n as n = 1, 3, 5, 7 or 9, the
immunoreactivity of purified ND-1 scFv-n was determined by ELISA. A multi-factorial
relationship model was employed to analyze the structural factors affecting scFv:
r nð Þ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
AB nð Þ  ABO½ 2 þ CD nð Þ  CDO½ 2
q
þ BC nð Þ  BCst½ 2. The relationship
between immunoreactivity and r-values revealed that fusion protein structure
approached the desired state when the r-value = 3. The immunoreactivity declined
as the r-value increased, but when the r-value exceeded a certain threshold, it
stabilized. We used a linear relationship to analyze structural factors affecting scFv
immunoreactivity.
Keywords: Single-chain Fv antibody (scFv), (Gly4Ser)n, End-to-end distance,
Homologous modeling, Meta MQAPIntroduction
Single-chain Fv antibody (scFv) is composed of immunoglobulin heavy- and light-
chain variable regions connected by a short peptide linker [1-3]. ScFv is an ideal tool
for the construction of single-chain bi-specific antibody fusion proteins [4-6]. Bivalent
antibodies derived from scFv using genetic engineering have a promising future in the
clinic. scFvs can be therapeutic and at the same time serve as a vector for delivering a
toxin [7]. In recent years, there has been progress in colorectal cancer diagnosis and
treatment using scFv as a carrier. However, achieving both high affinity and anti-tumor
activity can be difficult, particularly since both are needed to be effective. Studies have
shown that a proper linker can provide a scFv with biological activity more effective
for clinical applications [8-10]. Consequently, choosing and designing a proper linker
is a key consideration.© 2012 Zhang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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of proteins, and bioinformatics provides a powerful tool to study the structure-activity
relationship of fusion proteins [11-13]. Drug design based on structural simulation
incorporates 3D structure, including data from fusion proteins with various functional
domains and inter-peptide linkers [14-16]. Linkers that contain (G4S)n are the most
widely used [12,17], prompting us to examine its effects on the structure and function
of scFvs.Materials and methods
Materials
IC-2 and CCL-187 cells were cultured using standard conditions. IC-2 is a murine hy-
bridism cell line that secretes the monoclonal antibody ND-1, specific for human colo-
rectal carcinoma. CCL-187 is a human colorectal carcinoma cell line. The pET28a (+)
expression vector and E. coli BL21 were contributed by Prof. J. Yun, Xi'an (China). The
pMD18-T vector, E.coli JM109 competent cells, DNA polymerase, restriction enzymes,
and DNA recovery kits were purchased from TaKaRa Biotechnology (Shanghai, China).
mRNA purification kits and T4 DNA ligase were purchased from Pharmacia Biotech
(Shanghai, China). Anti-His6 tag antibody was obtained from Invitrogen (Foster City,
CA, USA). Ni-NTA resin was provided by QIAGEN (Shanghai, China), MDP and
99mTc were kindly provided by the Department of Nuclear Medicine of China Medical
University (Liaoning Province, China). Heavy chain primer 1 and 2, light chain primer
mix, linkers [(GGGGS)n] primer mix, and RS primer mix were purchased from Phar-
macia Biotech.
ND-1 scFv-n was constructed as previously described. Briefly, mRNA was extracted
from 5 × 106 IC-2 hybridism cells and cDNA synthesized by reverse transcription using
random primers. VH and VL genes were separately amplified from cDNA by PCR
using a heavy and light chain primer mix. The VH and VL gene fragments were recov-
ered and mixed in equimolar ratios for two PCR reactions, with the first one using a
linker primer mix for 7 cycles, followed by a second one using a RS primer mix for
30 cycles. As a result, VH and VL gene fragments were linked to form a scFv construct
by extension, with overlapping splicing PCR. The resulting ND-1 scFv-n construct was
cloned into pMD18-T and transformed into E. coli JM109, and positive clones identi-
fied by colony PCR and DNA sequencing.
Oligonucleotide primers S1 and S2 were designed to add EcoRI sites at the 5'-end of
ND-1scFv-n, and a HindIII site, or SalI site at the 3'-end. S1: 5'-CTGAATTCATGGCC
CAGGTGCAGCTGCAGC-3'; S2: 5'-CGCAAGCTTCTAGTCGACTTTCCAGCTTG
GTC-3'. pMD18-T-ND-1scFv-n was used as a template, and the product cloned into
the vector pET28a(+) after digestion with EcoRIand HindIII, and transformed into
competent E.coli BL21 cells for protein expression.Amino acid sequence
The amino acid sequence of the wild-type VH and wild-type VL are listed below [18],
and illustrated in Figure 1. The amino acid sequence of the VH-(G4S)n-VL is:
MAQVQLQQSGPGLVAPSQSLSITCTVSGFSLTTYDVHWVRQPPRKGLEWLGLVW
ANGRTNCTSALMSRISITRDTSKNQVFLTMNSLQTDDTAMYYCARGSYGAVDFWG
Figure 1 Map of VH-linker-VL.




Homology modeling, assessment, and optimization
The amino acid sequence of a protein determines its high-level structure. Determining
high-level protein structure relies on the identification of one or more known protein
"templates" that resemble the structure of the query sequence, and alignment of the
query sequence residues to the template residues. Swiss-Models can be used for hom-
ology modeling to search protein sequence and structure databases, such as the Protein
Data Bank (PDB) [19-21]. A three-dimensional model of the targeted molecule can be
obtained through homology modeling, and used to assess and optimize the model using
Meta MQAP [22,23].
Construction of coordinate system
PDB files were obtained from Swiss-Model with the videotext coordinate system (in
which the atomic coordinates are located), in order to facilitate protein structure com-
parison. The coordinate systems were constructed with Matlab7.0.
Determination of the origin of the coordinate system
The molecular weight of the atoms in the protein was used to calculate molecular
weight, and the centric was obtained using the atomic location of each atom. The cen-
tric is the origin of the new coordinate system [24].





















N: the number of all the atoms; M = 12.01 + 14.01 + 16.00 + 32.07 + 1.00;
Mi: molecular weight of atoms;
[Xk, Yk, Zk]: the original three-dimensional coordinates of atoms;
[X0, Y0, Z0]: the origin of the new coordinate system.
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atomic coordinates. This was regarded as the principal component of the matrix’s eigen-
vector of the new coordinate system’s X-axis, the sub-principal component of the vector
Y-axis, and used to build a coordinate system of the protein’s three-dimensional structure.












mk  Xak  Ybk  Zck ;
mk: molecule weight of atoms.
[Xk, Yk, Zk]: 3D coordinates of each atom.
The eigenvalues and eigenvectors of S were calculated, and the eigenvector calculated
corresponding to the maximum eigenvalue as the first axis (X axis is set, X = [X1, X2,
X3]), with the eigenvector corresponding to the second largest eigenvalue as the second
axis (Y axis set, Y = [Y1, Y2, Y3]), and similarly for the Z axis.
Analysis of End-to-end distance in fusion proteins
The End-to-end distance is the distance between the first and the last α-carbon atom
in a protein. We obtained this information and the X/Y/Z coordinates of the atoms
from the PDB database. The algorithm used is as follows:
A. Locate the first and last α-carbon atoms in the wild-type VH and VL, and the
same in the protein after introduction of (G4S)n.
B. Calculate End-to-end distance of wild-type VH (VL) and mutant VH (VL) after
introduction of (G4S)n.
C. Analyze the relationship between the End-to-end distance and n.
Biological experiments
Expression and purification of ND-1scFv-n.
pET28a(+)-ND-1scFv-n plasmids were constructed as expression vectors and trans-
formed into E. coli BL21 cells, which were grown in 100 ml LB broth with 50 mg/ml
Kanamycin at 37°C. When the culture attained an O.D. of 0.6, IPTG was added to a final
concentration of 1 mM, and cells were shaken at 37°C. After 3.5 h, the culture was centri-
fuged at 5,000 rpm for 10 min, and the cell pellets treated with lysis solution. After sonic-
ation and centrifugation, inclusion bodies containing scFv proteins were solubilized and
denatured in the presence of 6 M guanidine hydrochloride. Affinity chromatography on
Ni-NTA resin was use to purify scFv, and the column eluted sequentially with 8 M urea at
pH8.0, 6.5 and 4.2. The pH4.2 fraction, containing scFv, was collected and recaptured by
dialysis. Protein purity and concentration were determined by Bradford assay.
Western blot analysis
ND-1scFv-n proteins were detected by western blot analysis. BL21 transformed with
pET-28a(+)ND-1scFv-n was incubated separately in loading buffer (125 mmol/L Tris–
HCl, pH 6.8, 10% β-mercapto-ethanol, 4.6% SDS, 20% glycerol and 0.003% bromophe-
nol blue) for 5 min at 100°C, separated by sodium dodecyl sulfate polyacrylamide gel
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Non-specific binding sites were blocked for 1 h with 5% nonfat milk in TPBS (PBS con-
tained 0.05% Twin 20), and the membrane incubated overnight at 4°C with primary
antibody. After washing 3X in TPBS, the membrane was incubated with horseradish
peroxidase-conjugated goat anti-rabbit IgG for 2 h at room temperature, and washed
2X with TPBS. Immunoblot signal was detected by autoradiography using an enhanced
chemiluminescence detection kit.
ELISA assay for activity of ND-1scFv-n
CCL-187 cells (5 × 104) were grown in 96-well micro titer plates at 37°C for 24 h, fixed
with 2.5% glutaraldehyde and blocked with 1% BSA, followed by incubation with ND-
1IgG or ND-1scFv at 37°C for 2 h. After washing 3X with PBS, anti-His6 antibody was
added to wells with ND-1scFv-n and incubated. The plate was washed and HRP-labeled
goat anti-mouse IgG was added into both ND-IgG and ND-1scFv wells. After incubating
at 37°C for 2 h, TMB substrate was added, and samples incubated in darkness for 30 min.
The reaction was terminated with 1 M H2SO4. PBS was used as a negative control.
Results
Protein structures
A videotext of the coordinate system was built using the PDB atomic coordinates from
PDB files received from SWISS-MODEL, using Mat lab 7.0. The maps were used for com-
parison of the protein structures (Figure 2). Homology modeling using SWISS-MODEL
was used to evaluate the best evaluation method. Meta-MQAP was used to assess and
optimize the model. The accuracy score of the model and the root mean square (RMS)
deviation are shown in Table 1. The assessment result shows that the model is reliable.
Local alignment
The End-to-end distance of VH (AB), VL (CD) and linker (BC), at different n values
are presented in Table 2. It appears that linker BC was relatively stable from n = 1-7,
and there were changes in the End-to-end distances for AB and CD. When the n valueFigure 2 Map of VH-(G4S)n-VL (LL: linker length; red line: VH peptide; green line: linker peptide;
blue line: VL peptide).
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fluctuations. The End-to-end distance of VL basically did not change except when n = 6
and n = 0. The data suggests that the major factor for this was that the median value of
BC was about 22.6622 in the End-to-end distances of linked peptides. Although the
End-to-end distance changes were small, there were fluctuations in the value of
AB and CD near the ideal state. Thus, the effects of the linked peptide structural
factors (r) on VH and VL can be represented in the following equation: r nð Þ ¼ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
AB nð Þ  ABO½ 2 þ CD nð Þ  CDO½ 2
q
þ BC nð Þ  BCst½ 2. The ideal fusion protein struc-
ture should have a stable structure with the linker peptide of minr nð Þ , as shown in
Figure 3. The results of r were obtained from the corresponding linker length. The
r-values were 36.8161, 8.0150, 0.8415, 22.1579, 24.4747, 582.2451, 46.8344, 88.6852,
and 112.3846, with a median value of 24.4747.
The results suggest that when n = 3, the r-value was the smallest, and the structure of
fusion proteins was closest to the ideal state. The r-values increased when n increased
and hence the linker length increased, in which VH and VL structure would be
impacted to a greater extent. When n was 6, the r value was the most unsatisfactory.Table 2 The value of AB\CD\BC at different values of n
Sequence BC AB CD
Wild-type VH 36.7939
Wild-type VL 14.4022
n = 0 29.6393 6.8006
n = 1 16.7822 34.9540 13.1215
n = 2 22.6653 44.7992 14.0089
n = 3 22.6622 37.5364 14.0063
n = 4 19.6630 23.6371 14.0095
n = 5 23.7909 13.59664 14.0052
n = 6 46.6356 37.536 21.8867
n = 7 27.4472 12.8588 14.0167
n = 8 13.9244 24.4632 14.0393
n = 9 12.5718 26.2316 14.0417
Figure 3 The diagram shows the relationship between the length of linked peptides and r value.
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Plasmids ND-1scFv-pET28a (+) were transformed into E. coli BL21, and protein ex-
pression induced with IPTG. Western blot analysis indicated that BL21 lysates
expressed scFv-n proteins with bands of 30 kDa (Figure 4). The sequences encoding
the short His-tag peptide were upstream of the multi-cloning site (MCS) of vector
pET28a (+), and ND-1scFv-n was expressed as a recombinant fusion protein. Western
blot analysis showed that scFv-n protein is expressed in inclusion bodies in the super-
natant of BL21 lysates. Inclusion body protein was purified to 94% by metal affinity
chromatography using Ni-NTA resin, which binds to the His-tag protein marker on
the N terminal end of scFv.
Analysis of the relationship between immunoreactivity and End-to-end distance
The immunoreactivity of purified ND-1scFv-n was determined by ELISA. scFv-n exhi-
bits an immunoreactivity similar to the parental ND-1 antibody, and demonstrated
good binding to CCL-187 cells expressing colorectal carcinoma associated antigen
LEA. This suggests that scFv-n retains good specificity and activity.Figure 4 Western blot analysis of ND-1scFv-n in BL21 cells. 1: Expression of pET28a (+)-ND-1scFv with
(G4S)1; 2: Expression of pET28a (+)-ND-1scFv with (G4S)3; 3: Expression of pET28a (+)-ND-1scFv with (G4S)5; 4:
Expression of pET28a (+)-ND-1scFv with (G4S)7; 5: Expression of pET28a (+)-ND-1scFv with (G4S)9.
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values. The immunoreactivity declined with increasing r-values. It changed significantly
when the r-value was less than 42.3716. When the r-value exceeded this value, immu-
noreactivity became relatively stable (Figure 5).
Discussion
Homology modeling has been successfully applied to interpreting the correlation of
protein sequence, structure, and function. Using a structural model, multiple sequences
of orthologues proteins can be compared and evaluated according to the restrictions of
natural selection and requirements of protein folding, stability, dynamics, and function.
Homology modeling can help determine which functional groups the protein belongs
to based on the analyses of conserved residues in the binding site. Homology modeling
also plays an important role in computer-aided drug design [25,26].
One basic issue in the study of protein structure is structural comparison. The rela-
tively direct comparison method is to consider the protein as a rigid structure com-
posed of a series of point sets, then compare the corresponding residues of different
proteins. At the beginning, a rigid superposing method was used (to translate and ro-
tate the spatial structure of the protein to find the corresponding residues between two
proteins) [27,28]. However, Chen proposed using a weight distribution of the atoms
composing the protein, and to use this to calculate the protein’s gravity center, using a
3 × 3 matrix composed of second-order moments [24]. On this basis, one can use prin-
cipal component analysis (PCA) to find the main and secondary axis. The best rigid
superposition is obtained through superposing the gravity centers of the proteins and
then rotating them to let their main axes superimpose. In this study, we used the mo-
lecular weight of the atoms to get the centric according to the coordinates of each
atom.
It is recognized that fusion proteins have varied affinity and anti-tumor activity com-
pared to the original molecules, due in large part to the structural alterations of the fu-
sion proteins [4,28-31]. The inter-peptide linkers can be optimized with computer-
aided design [32]. Based on homology modeling of derivatives [33], future designs of
inter-peptide linkers can be viewed as solving an equation. The structure and character-
istics of target molecules, and the composition, length, and flexibility of inter-peptide
linker should be taken into consideration [34,35].
In previous studies [35-37], the length and composition of the linkers that have been
used to link VH and VL on bivalent single-chain antibody often impact stability and
function. Linkers may be too short to fold correctly by intermolecular static influence
or be too long to ameliorate the immunogenicity of antibodies. To satisfy these require-
ments, several design strategies have been developed. One approach is to use theTable 3 The relationship between r-value and the corresponding biology






Figure 5 The linear relationship between the r value and ND-lsc(Fv)2-n immune reactivity.
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been used to construct bivalent single-chain antibodies targeting colorectal cancer with
linkers of 5-15 amino acids [18,36]. With a 5 amino acid linker, immune reactivity was un-
satisfactory, possibly because the linker was too short to provide an effective distance for
the two antigen-binding sites, which affected the stability of the cross-linked protein. The
linker with 15 amino acids tended to fold correctly and retained the bivalent single-chain
antibody's affinity and capacity. It has long been noted that sufficient flexibility and length
for VH and VL domains are achieved by assembling them in the natural Fv orientation to
form a monovalent antigen-binding site, which is comparable to the Fab fragment of na-
tive antibodies. It has also been shown that the length and sequence of the linker peptide
significantly affects scFv expression and stability [36].
It should be pointed out that the impact of linker length on the activity and affinity
of engineered antibodies depends strongly on the distance between the N- and C-
terminal of the VH domain [37]. A certain degree of flexibility in the linker is required
for the functional cooperation of the two subunits. The goal of this study was to
characterize novel scFvs and to quantify the impact of linker peptide on binding affin-
ity. Using computer guided homology, scFvs with different linker peptides were pro-
posed based upon the activity and the End-to-end distance. Our aim was to evaluate
the impact of (G4S)n on the structure and function of VH and VL, and to find the rela-
tionship between VH/VL’s End-to-end distance and n (or BC) on bivalent single-chain
antibodies targeting colorectal cancer. A multi-factor relationship model was estab-
lished to evaluate VH and VL structural factors using the following formula: r nð Þ ¼ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
AB nð Þ  ABO½ 2 þ CD nð Þ  CDO½ 2
q
þ BC nð Þ  BCst½ 2 . Based on simulated data and
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noreactivity and r-values. The immunoreactivity declines as the r-value increases. Fu-
sion protein structure is ideal when the r = 3. When the n value is 6, protein structure
is least satisfactory. However, further exploration of this relationship is needed. Indeed,
the expression level and activity of scFv depends largely on the length and sequence of
linker. Thus, successful construction of a scFv depends on the selection of a linker that
neither interferes with the folding and association of VH and VL domains nor reduces
the stability and recognition abilities of the Fv molecule.
In summary, based on the databases of natural protein structures and their associated
functions, we predicted the structure and function of fusion proteins by homology
modeling and further conducted biological experiments to validate our calculations.
Thus, a dual approach that incorporates molecular modeling and linker design of engi-
neered antibodies with quantitative determination of antibody affinity is useful to
optimize construction. Our approach provides not only a rationale for designing novel
engineered antibodies using molecular modeling, but also provides new insight into
quantifying antibody binding affinity, especially at low protein concentration. A com-
bination of bioinformatics and genetic research may therefore be beneficial in exploring
new agents for genetic engineering of antibodies.
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